TIP_link_300x300.jpg
Blood Temperature Indicator Market Worth $504.37 Mn, Globally, by 2028 at 12.9% CAGR - Exclusive Report by The Insight Partners
May 18, 2022 08:58 ET | The Insight Partners
New York, May 18, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Blood Temperature Indicator Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by...
PRPO logo.png
Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference
April 26, 2022 10:00 ET | Precipio, Inc.
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), is excited to announce its participation and the presentation of HemeScreen,...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
February 28, 2022 16:01 ET | FibroGen, Inc.
Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results
February 14, 2022 07:00 ET | FibroGen, Inc.
SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on Monday, February 28 after the market close....
Image
Nemysis Ltd Announces Appointment of Antonino Santoro as Adviser for Scientific Affairs
February 07, 2022 04:30 ET | Nemysis Limited
DUBLIN, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Nemysis Ltd today announces the appointment of Antonino Santoro to its Executive Team as Adviser for Scientific Affairs. Antonino Santoro is a Chemist,...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference
January 04, 2022 07:00 ET | FibroGen, Inc.
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the H.C....
22157.jpg
Worldwide Hematology Testing Industry to 2027 - by Product, Test Type, End-user and Geography
December 22, 2021 05:18 ET | Research and Markets
Dublin, Dec. 22, 2021 (GLOBE NEWSWIRE) -- The "Hematology Testing Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. In-depth Analysis and...
PRPO logo.png
New York State Approves Precipio’s HemeScreen for POL clinical use
November 18, 2021 10:00 ET | Precipio, Inc.
NEW HAVEN, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that its HemeScreen RUO assay has received the required approval from...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2021
October 25, 2021 07:00 ET | FibroGen, Inc.
SAN FRANCISCO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that analyses from the global Phase 3 roxadustat clinical program will be presented at the American...
PRPO logo.png
American Oncology Network Partners with Precipio to Bring HemeScreen® into AON’s Laboratory
August 26, 2021 10:00 ET | Precipio, Inc.
NEW HAVEN, Conn. and FORT MYERS, Fla., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), and American Oncology Network, LLC (AON), a high-growth...